期刊
NATURE
卷 557, 期 7704, 页码 177-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41586-018-0090-6
关键词
-
资金
- HHMI
- Stanford CNC Program
- Stanford Photonics Research Center
- Pfizer
- Stanford
- Helen Hay Whitney Foundation
- US National Institutes of Health
- US National Science Foundation
- Bill & Melinda Gates Foundation
- Swiss National Science Foundation
- GG Technologies gift fund
Loss of dopamine in Parkinson's disease is hypothesized to impede movement by inducing hypo-and hyperactivity in striatal spiny projection neurons (SPNs) of the direct (dSPNs) and indirect (iSPNs) pathways in the basal ganglia, respectively. The opposite imbalance might underlie hyperkinetic abnormalities, such as dyskinesia caused by treatment of Parkinson's disease with the dopamine precursor L-DOPA. Here we monitored thousands of SPNs in behaving mice, before and after dopamine depletion and during L-DOPA-induced dyskinesia. Normally, intermingled clusters of dSPNs and iSPNs coactivated before movement. Dopamine depletion unbalanced SPN activity rates and disrupted the movement-encoding iSPN clusters. Matching their clinical efficacy, L-DOPA or agonism of the D-2 dopamine receptor reversed these abnormalities more effectively than agonism of the D-1 dopamine receptor. The opposite pathophysiology arose in L-DOPA-induced dyskinesia, during which iSPNs showed hypoactivity and dSPNs showed unclustered hyperactivity. Therefore, both the spatiotemporal profiles and rates of SPN activity appear crucial to striatal function, and next-generation treatments for basal ganglia disorders should target both facets of striatal activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据